https://www.hcplive.com/view/sglt2-inhibitors-glaucoma-risk-type-2-diabetes-patients
0
0
11/3/23 at 9:45pm
Organization
Hcplive.com
Author
Kevin Kunzmann
37 words
0
Comments
New AAO 2023 data suggests drugs like dapagliflozin and empagliflozin may provide greater protection against glaucoma than GLP-1 agonists or DDP-4 inhibitors.
You are the first to view
Create an account
or login to join the discussion